Phoqus Group

Phoqus Group was a UK-based drug delivery company that specialized in the development of innovative oral dosage forms using its proprietary electrostatic coating technology. The company's flagship platform, Leocite, utilized a dry powder coating process similar to laser printing to apply precise layers to tablets, enabling controlled release and the combination of multiple active ingredients. Phoqus focused on reformulating established drugs to improve patient compliance and therapeutic outcomes in areas such as diabetes, cardiovascular disease, and Parkinson's disease. Despite establishing partnerships with major firms like Cardinal Health and Schering-Plough, the company faced significant funding challenges. Phoqus Group was listed on the London Stock Exchange's AIM market before entering administration in early 2009. The company's unique technology aimed to eliminate the need for solvents and heat in the coating process, offering advantages for sensitive pharmaceutical compounds.